Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy

OncoImmunology

Volumn 6, Issue 4, 2017, Pages

  Roussel, Hélène ^a,b,c   De Guillebon, Eléonore ^a,b,c   Biard, Lucie ^d   Mandavit, Marion ^a,c   Gibault, Laure ^b   Fabre, Elisabeth ^b   Antoine, Martine ^e,f   Hofman, Paul ^g   Beau Faller, Michèle ^h   Blons, Hélène ^b   Danel, Claire ⁱ   Barthes, Françoise Le Pimpec ^b   Gey, Alain ^a,b   Granier, Clémence ^a,b,c   Wislez, Marie ^e,f   Laurent Puig, Pierre ^b   Oudard, Stéphane ^a,b,c   Bruneval, Patrick ^b   Badoual, Cécile ^a,b,c   Cadranel, Jacques ^e,f   Tartour, Eric ^a,b,c   more..

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c Equipe Labellisée Par la Ligue Nationale Contre le Cancer 20112013   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e HÔPITAL TENON   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g PASTEUR HOSPITAL   (France)

^h HÔPITAL DE HAUTEPIERRE   (France)

ⁱ BICHAT HOSPITAL   (France)

Author keywords

ALK positive adenocarcinoma; immunotherapy; in situ quantitative cell imaging; predictive biomarker; tumor microenvironment

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BIOLOGICAL MARKER; CD8 ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR;

ADENOCARCINOMA; ARTICLE; CANCER IMMUNOTHERAPY; CELL COUNT; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; ESTIMATED GLOMERULAR FILTRATION RATE; FLUORESCENCE ANALYSIS; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE TEST; MUTATION; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PHENOTYPE; STROMA CELL; TUMOR MICROENVIRONMENT;

EID: 85016074688     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1286437     Document Type: Article

References (49)

1. Boi M, Zucca E, Inghirami G, Bertoni F. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. Br J Haematol 2015; 168(6):771-83; PMID:25559471; http://dx.doi.org/10.1111/bjh.13265
2. Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 2013; 13(11):772-87; PMID:24132104; http://dx.doi.org/10.1038/nrc3612
3. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448(7153):561-6; PMID:17625570; http://dx.doi.org/10.1038/nature05945
4. Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer:Results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016; 387(10026):1415-26; PMID:26777916; http://dx.doi.org/10.1016/S0140-6736(16)00004-0
5. Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours:Learning from lung cancer. Nat Rev Clin Oncol 2014; 11(8):473-81; PMID:24981256; http://dx.doi.org/10.1038/nrclinonc.2014.104
6. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373(2):123-35; PMID:26028407; http://dx.doi.org/10.1056/NEJMoa1504627
7. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373(17):1627-39; PMID:26412456; http://dx.doi.org/10.1056/NEJMoa1507643
8. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):A randomised controlled trial. Lancet 2016; 387(10027):1540-50; PMID:26712084; http://dx.doi.org/10.1016/S0140-6736(15)01281-7
9. Yadav M, Delamarre L. Immunotherapy. Outsourcing the immune response to cancer. Science 2016; 352(6291):1275-6; PMID:27284181; http://dx.doi.org/10.1126/science.aag1547
10. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348(6230):124-8; PMID:25765070; http://dx.doi.org/10.1126/science.aaa1348
11. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372(26):2509-20; PMID:26028255; http://dx.doi.org/10.1056/NEJMoa1500596
12. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy:A single-arm, multicentre, phase 2 trial. Lancet 2016; 387(10031):1909-20; PMID:26952546; http://dx.doi.org/10.1016/S0140-6736(16)00561-4
13. Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, Durno C, Krueger J, Cabric V, Ramaswamy V, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 2016; 34(19):2206-11; PMID:27001570; http://dx.doi.org/10.1200/JCO.2016.66.6552
14. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373(19):1803-13; PMID:26406148; http://dx.doi.org/10.1056/NEJMoa1510665
15. Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 2015; 350(6266):1387-90; PMID:26516200; http://dx.doi.org/10.1126/science.aad1253
16. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372(21):2018-28; PMID:25891174; http://dx.doi.org/10.1056/NEJMoa1501824
17. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):A multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016; 387(10030):1837-46; PMID:26970723; http://dx.doi.org/10.1016/S0140-6736(16)00587-0
18. Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2016; 34(25):2980-7; PMID:27354485; http://dx.doi.org/10.1200/JCO.2016.66.9929
19. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515(7528):568-71; PMID:25428505; http://dx.doi.org/10.1038/nature13954
20. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20(19):5064-74; PMID:24714771; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271
21. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, et al. Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma. Cell 2016; 165(1):35-44; PMID:26997480; http://dx.doi.org/10.1016/j.cell.2016.02.065
22. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515(7528):563-7; PMID:25428504; http://dx.doi.org/10.1038/nature14011
23. McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR, Fasso M, Wang YV, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma:Long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 2016; 34(8):833-42; PMID:26755520; http://dx.doi.org/10.1200/JCO.2015.63.7421
24. Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 2015; 75(11):2139-45; PMID:25977340; http://dx.doi.org/10.1158/0008-5472.CAN-15-0255
25. Ock CY, Keam B, Kim S, Lee JS, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS. Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration. Clin Cancer Res 2016; 22(9):2261-70; PMID:26819449; http://dx.doi.org/10.1158/1078-0432.CCR-15-2834
26. Ait-Tahar K, Cerundolo V, Banham AH, Hatton C, Blanchard T, Kusec R, Becker M, Smith GL, Pulford K. B and CTL responses to the ALK protein in patients with ALK-positive ALCL. Int J Cancer 2006; 118(3):688-95; PMID:16114011; http://dx.doi.org/10.1002/ijc.21410
27. Passoni L, Gallo B, Biganzoli E, Stefanoni R, Massimino M, Di Nicola M, Gianni AM, Gambacorti-Passerini C. In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas. Haematologica 2006; 91(1):48-55; PMID:16434370
28. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, Wang HY, Wysocka M, Cheng M, Ruggeri BA, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A 2008; 105(52):20852-7; PMID:19088198; http://dx.doi.org/10.1073/pnas.0810958105
29. Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J, Harada T, Matsumoto K, Takayama K, Takamori S, et al. Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer. Clin Cancer Res 2015; 21(17):4014-21; PMID:26019170; http://dx.doi.org/10.1158/1078-0432.CCR-15-0016
30. Voena C, Menotti M, Mastini C, Di Giacomo F, Longo DL, Castella B, Merlo ME, Ambrogio C, Wang Q, Minero VG, et al. Efficacy of a cancer vaccine against ALK-rearranged lung tumors. Cancer Immunol Res 2015; 3(12):1333-43; PMID:26419961; http://dx.doi.org/10.1158/2326-6066.CIR-15-0089
31. Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer:A retrospective analysis. Clin Cancer Res 2016; 22(18):4585-93; PMID:27225694; http://dx.doi.org/10.1158/1078-0432.CCR-15-3101
32. Koh J, Go H, Keam B, Kim MY, Nam SJ, Kim TM, Lee SH, Min HS, Kim YT, Kim DW, et al. Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma:Comparison with histology and driver oncogenic alteration status. Mod Pathol 2015; 28(9):1154-66; PMID:26183759; http://dx.doi.org/10.1038/modpathol.2015.63
33. D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 2015; 112(1):95-102; PMID:25349974; http://dx.doi.org/10.1038/bjc.2014.555
34. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with b7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4(127):127ra37; PMID:22461641; http://dx.doi.org/10.1126/scitranslmed.3003689
35. Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, Xu H, Meeker AK, Fan J, Cheadle C, et al. Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma:Implications for PD-1 pathway blockade. Clin Cancer Res 2015; 21(17):3969-76; PMID:25944800; http://dx.doi.org/10.1158/1078-0432.CCR-15-0244
36. Yoshimura M, Tada Y, Ofuzi K, Yamamoto M, Nakatsura T. Identification of a novel HLA-A 02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene. Oncol Rep 2014; 32(1):33-9; PMID:24842630
37. Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73(1):128-38; PMID:23135914; http://dx.doi.org/10.1158/0008-5472.CAN-12-2606
38. Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 2016; 22(4):433-8; PMID:26901407; http://dx.doi.org/10.1038/nm.4051
39. Hellmann MD, Gettinger S, JW G, Brahmer J, Borghaei H, Chow LQ, Ready N, Gerber DE, Juergens R, Shepherd F, et al. CheckMate 012:Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. J Clin Oncol 2016; 34.
40. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012):an open-label, multicentre, phase 1b trial. Lancet Oncol 2016; 17(7):956-65; PMID:27247226; http://dx.doi.org/10.1016/S1470-2045(16)30066-3
41. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016; 351(6280):1463-9; PMID:26940869; http://dx.doi.org/10.1126/science.aaf1490
42. Chen DS, Irving BA, Hodi FS. Molecular pathways:Next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012; 18(24):6580-7; PMID:23087408; http://dx.doi.org/10.1158/1078-0432.CCR-12-1362
43. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015; 160(1-2):48-61; PMID:25594174; http://dx.doi.org/10.1016/j.cell.2014.12.033
44. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, Holt RA. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 2014; 24(5):743-50; PMID:24782321; http://dx.doi.org/10.1101/gr.165985.113
45. Mansuet-Lupo A, Alifano M, Pecuchet N, Biton J, Becht E, Goc J, Germain C, Ouakrim H, Regnard JF, Cremer I, et al. Intratumoral immune cell densities are associated with lung adenocarcinoma gene alterations. Am J Respir Crit Care Med 2016; 194(11):1403-1412; PMID:27299180
46. Cha YJ, Kim HR, Lee CY, Cho BC, Shim HS. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Lung Cancer 2016; 97:73-80; PMID:27237031; http://dx.doi.org/10.1016/j.lungcan.2016.05.001
47. Blank CU, Haanen JB, Ribas A, Schumacher TN. Cancer immunology. The “cancer immunogram.” Science 2016; 352(6286):658-60; PMID:27151852; http://dx.doi.org/10.1126/science.aaf2834
48. Bougherara H, Mansuet-Lupo A, Alifano M, Ngo C, Damotte D, Le Frere-Belda MA, Donnadieu E, Peranzoni E. Real-time imaging of resident T cells in human lung and ovarian carcinomas reveals how different tumor microenvironments control T lymphocyte migration. Front Immunol 2015; 6:500; PMID:26528284; http://dx.doi.org/10.3389/fimmu.2015.00500
49. Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Calio A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1):Sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One 2015; 10(6):e0130142; PMID:26086854; http://dx.doi.org/10.1371/journal.pone.0130142